# OnCo record impower110 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/impower110/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "impower110", "NCT02409342" ;
  schema:name "IMpower110"@en ;
  schema:description "Showed that for people whose tumours are covered in PD-L1, a single immunotherapy drug can replace first-line chemotherapy, adding about seven months of life."@en ;
  schema:url <https://onco.cc/trials/impower110/> ;
  schema:dateModified "2026-09-25"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02409342>, <https://doi.org/10.1056/NEJMoa1917346>, <https://www.nice.org.uk/guidance/ta705> ;
  onco:status "positive" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/pdl1-high-nsclc/>, <https://onco.cc/cancers/nsclc/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/companion-diagnostic/>, <https://onco.cc/technologies/platinum/> ;
  onco:targets <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/carboplatin/>, <https://onco.cc/drugs/cisplatin/> ;
  onco:companies <https://onco.cc/companies/roche-genentech/> ;
  onco:terms <https://onco.cc/terms/tps/>, <https://onco.cc/terms/pd-l1-testing/>, <https://onco.cc/terms/tmb/> ;
  onco:trials <https://onco.cc/trials/keynote-024-189/>, <https://onco.cc/trials/keynote-042/>, <https://onco.cc/trials/empower-lung-1/> .